Actas urologicas espanolas · 2010
[Conservative treatment of Peyronie's disease: colchicine vs. colchicine plus vitamin E].
Сравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cortés-González J R, Glina S
Аннотация
OBJECTIVE: To retrospectively review the response of patients with Peyronie's disease (PD) treated with colchicine as monotherapy and colchicine plus Vitamin E.
MATERIAL AND METHODS: We evaluated 100 men with PD. A dose of 1.5 mg/day oral Colchicine as monotherapy (CCM) was given to 59 patients and 1.5/800 mg/day oral Colchicine/Vitamin E (CCVE) to 41. Response was categorized as follows: Good response, when at least 2 of the following conditions were achieved: Decrease/stabilization of curvature and/or plaque and/or pain relief. Partial response if one of the former conditions were observed. No response and worsening. No statistical differences between groups were found.
RESULTS: Good response was observed in 39% vs 41% in the CCM and CCVE groups respectively. When looking at each variable, we observed improvement on the plaque's size in 36 vs 29%, pain relief in 46 vs 57% and curvature 32 vs 33% in the CCM and CCVE respectively. None of these differences were statistically significant.
CONCLUSION: Oral conservative treatment with CCVE failed to show statistically significant differences in efficacy in pain relief, penile curvature or plaque size against CCM in this study. However, there is slight evidence of a positive prognostic effect on the conservative treatment when history of previous unsuccessful PD treatment was recorded, this was statistically significant in the CCVE group, supporting the theory of a combined treatment. A randomized double blind placebo controlled study with a sample size calculation should be performed to confirm our results.
MATERIAL AND METHODS: We evaluated 100 men with PD. A dose of 1.5 mg/day oral Colchicine as monotherapy (CCM) was given to 59 patients and 1.5/800 mg/day oral Colchicine/Vitamin E (CCVE) to 41. Response was categorized as follows: Good response, when at least 2 of the following conditions were achieved: Decrease/stabilization of curvature and/or plaque and/or pain relief. Partial response if one of the former conditions were observed. No response and worsening. No statistical differences between groups were found.
RESULTS: Good response was observed in 39% vs 41% in the CCM and CCVE groups respectively. When looking at each variable, we observed improvement on the plaque's size in 36 vs 29%, pain relief in 46 vs 57% and curvature 32 vs 33% in the CCM and CCVE respectively. None of these differences were statistically significant.
CONCLUSION: Oral conservative treatment with CCVE failed to show statistically significant differences in efficacy in pain relief, penile curvature or plaque size against CCM in this study. However, there is slight evidence of a positive prognostic effect on the conservative treatment when history of previous unsuccessful PD treatment was recorded, this was statistically significant in the CCVE group, supporting the theory of a combined treatment. A randomized double blind placebo controlled study with a sample size calculation should be performed to confirm our results.